News coverage about Derma Sciences (NASDAQ:DSCI) has trended somewhat positive on Thursday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Derma Sciences earned a news impact score of 0.14 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 45.8596673030494 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

COPYRIGHT VIOLATION NOTICE: This article was published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/14/derma-sciences-dsci-receives-daily-news-impact-rating-of-0-14.html.

Derma Sciences Company Profile

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Insider Buying and Selling by Quarter for Derma Sciences (NASDAQ:DSCI)

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.